Denosumab (Xgeva®)

Newfoundland & LabradorCommon name: Denosumab
Brand name: Xgeva®

What is Denosumab?

Denosumab is a monoclonal antibody that is used to treat osteoporosis in men diagnosed with prostate cancer. Denosumab works by stopping bone cells (osteoclasts) from breaking down bone structure.

How is Denosumab administered?

Denosumab is administered by subcutaneous injection (under the skin).

What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received denosumab. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Diarrhea
  • Fatigue
  • Nausea
  • Rash
  • Skin changes
  • Weakness

Is Denosumab covered in my province or territory?*

Denosumab is covered by provincial drug programs in:
  • British Columbia
  • Manitoba
  • New Brunswick
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
Denosumab is not covered by provincial drug programs in:
  • Alberta
  • Newfoundland & Labrador
  • Northwest Territories
  • Prince Edward Island
  • Yukon
​Unknown if denosumab is covered by provincial drug programs in:
  • ​Nunavut

VICTORY Program – Supportive Care (XGEVA)
Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Please call 1-888-706-4717 for more information and to see if you qualify for this program.

Last Reviewed: July 2017

Help us take the first steps toward prevention. Donate Now

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.

Click here for news archive